AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29155001 — intervention group
Group type: COMPARATOR
Intervention: Non-harvested side (internal control)
Number of subjects: 40
Study 27163301 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartile 4 (lowest muscle ratio)
Number of subjects: 2383
Study 27163301 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm and leg muscle mass to total body weight ratio
Number of subjects: 2383
Study 24616451 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (HFD)
Number of subjects: 29
Study 24616451 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat diet (LFD)
Number of subjects: 29
Study 20863395 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention (multimodal approach including patient prompts, clinician prompts, outreach, low-literacy education tools)
Number of subjects: 0
Study 20863395 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention (control group)
Number of subjects: 0
Study 16236738 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab plus adjuvant chemotherapy (doxorubicin and cyclophosphamide followed by paclitaxel) for 52 weeks
Number of subjects: 394
Study 16236738 — intervention group
Group type: COMPARATOR
Intervention: Control group (doxorubicin and cyclophosphamide followed by paclitaxel without trastuzumab)
Number of subjects: 394
Study 12166560 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole and budesonide
Number of subjects: 37
Study 12166560 — intervention group
Group type: COMPARATOR
Intervention: Itraconazole alone
Number of subjects: 37
Study 12166560 — intervention group
Group type: COMPARATOR
Intervention: Control group (CF patients)
Number of subjects: 37
Study 9784040 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (125 or 250 mg/day) for 1 week
Number of subjects: 107
Study 9784040 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (125 or 250 mg/day) for 2 weeks
Number of subjects: 107
Study 9784040 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine (125 or 250 mg/day) for 4 weeks
Number of subjects: 107
Study 9784040 — intervention group
Group type: COMPARATOR
Intervention: Control group (Griseofulvin or Ketoconazole not specified)
Number of subjects: 107
Study 8112206 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin injection (with adrenalin: n = 11; without adrenalin: n = 29)
Number of subjects: 80
Study 8112206 — intervention group
Group type: EXPERIMENTAL
Intervention: Polidocanol injection (with adrenalin: n = 17; without adrenalin: n = 8)
Number of subjects: 80
Study 8112206 — intervention group
Group type: COMPARATOR
Intervention: Adrenalin injection alone (n = 15)
Number of subjects: 80
Study 2468838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 515
Study 2468838 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 515
Study 2468838 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Nifedipine and Metoprolol
Number of subjects: 515
Study 2468838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (in patients already on beta-blocker)
Number of subjects: 515
Study 2468838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 515
Study 11286323 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine L‐tartrate ER 8 mg (2 x 4 mg capsules) with a standardised high‐fat breakfast
Number of subjects: 17
Study 11286323 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine L‐tartrate ER 8 mg (2 x 4 mg capsules) on an empty stomach
Number of subjects: 17
Study 11286323 — intervention group
Group type: COMPARATOR
Intervention: tolterodine L‐tartrate IR 4 mg (2 x 2 mg tablets) administered in the fasting state
Number of subjects: 17
Study 11286323 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety endpoints
Number of subjects: 17
Study 31590154 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise combined with aerobic or impact training for 3 to 6 months
Number of subjects: 152
Study 30099530 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin with a run-in period (test dose)
Number of subjects: 1000
Study 30099530 — intervention group
Group type: COMPARATOR
Intervention: Statin without a run-in period (no test dose)
Number of subjects: 1000
Study 26334255 — intervention group
Group type: EXPERIMENTAL
Intervention: SN2‐palmitate formula (n=57)
Number of subjects: 171
Study 26334255 — intervention group
Group type: COMPARATOR
Intervention: Control formula (n=57)
Number of subjects: 171
Study 25895202 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin D (VD group)
Number of subjects: 200
Study 25895202 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 IU of vitamin D + 600 mg of calcium lactate (VD-Ca group)
Number of subjects: 200
Study 25895202 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrients with 400 IU of vitamin D + 600 mg of calcium lactate (MMN-VD-Ca group)
Number of subjects: 200
Study 25895202 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL group)
Number of subjects: 200
Study 25895202 — intervention group
Group type: EXPERIMENTAL
Intervention: All supplemented groups (VD, VD-Ca, MMN-VD-Ca)
Number of subjects: 200
Study 22036512 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (IUS)
Number of subjects: 0
Study 22036512 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-containing intrauterine contraceptive device (IUCD)
Number of subjects: 0
Study 22036512 — intervention group
Group type: COMPARATOR
Intervention: Control group (no device inserted)
Number of subjects: 0
Study 20179914 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg once daily for 5 days
Number of subjects: 12
Study 20179914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17268208 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP) therapy
Number of subjects: 450
Study 15297200 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (1.0 mg/m(2)/day on days 1 to 3) and Carboplatin (AUC 4 on day 1) followed by Paclitaxel (175 mg/m(2) via 3‐h IV infusion on day 1) and Carboplatin (AUC 5 on day 1)
Number of subjects: 45
Study 12203747 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient initiated follow up (n = 30, age range 53‐87 years)
Number of subjects: 61
Study 12203747 — intervention group
Group type: COMPARATOR
Intervention: Standard clinic follow up (n = 31, age range: 48‐83 years)
Number of subjects: 61
Study 9830856 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-based formula (AB) - (age in years +16) / 4
Number of subjects: 174
Study 9830856 — intervention group
Group type: COMPARATOR
Intervention: Broselow pediatric resuscitation tape
Number of subjects: 174
Study 9830856 — intervention group
Group type: COMPARATOR
Intervention: Age-based formula (AB) - (age in years +18) / 4
Number of subjects: 174
Study 8089728 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (retinyl palmitate) 210 mumol
Number of subjects: 200
Study 8089728 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 2510268 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil, 300 micrograms b.d.
Number of subjects: 355
Study 2510268 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine, 150 mg b.d.
Number of subjects: 355
Study 1102277 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiothixene (Navane, Pfizer)
Number of subjects: 24
Study 1102277 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine
Number of subjects: 24
Study 1102277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31006818 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium cereal (LSC)
Number of subjects: 39
Study 31006818 — intervention group
Group type: COMPARATOR
Intervention: Regular-sodium cereal (RSC)
Number of subjects: 39
Study 29179773 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-s sustained inflation
Number of subjects: 40
Study 29179773 — intervention group
Group type: COMPARATOR
Intervention: Five repeated inflations of 2-3 s
Number of subjects: 40
Study 24619991 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal Qi exercise (90 minutes, twice a week for 12 weeks)
Number of subjects: 70
Study 24619991 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study 23708168 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy (hemoglobin level ≥10 g/dL)
Number of subjects: 110
Study 23708168 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy (hemoglobin <8 g/dL or symptoms from anemia)
Number of subjects: 110
Study 23708168 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal transfusion strategy
Number of subjects: 110
Study 23708168 — intervention group
Group type: COMPARATOR
Intervention: Restrictive transfusion strategy
Number of subjects: 110
Study 21387981 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral irrigator with prototype jet tip
Number of subjects: 108
Study 21387981 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral irrigator with standard jet tip
Number of subjects: 108
Study 21387981 — intervention group
Group type: COMPARATOR
Intervention: Waxed dental floss
Number of subjects: 108
Study 19217741 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Numeracy Questionnaire (ANQ)
Number of subjects: 80
Study 16827932 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome
Number of subjects: 166
Study 15570285 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyurea (30 mg/kg/day)
Number of subjects: 179
Study 15570285 — intervention group
Group type: COMPARATOR
Intervention: Busulphan (0.1 mg/kg/day)
Number of subjects: 179
Study 15570285 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation (BMT)
Number of subjects: 179
Study 15570285 — intervention group
Group type: COMPARATOR
Intervention: Non-transplanted patients
Number of subjects: 179
Study 11122135 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 microg/kg G‐CSF once daily (n = 25)
Number of subjects: 50
Study 11122135 — intervention group
Group type: COMPARATOR
Intervention: 5 microg/kg G‐CSF twice daily (n = 25)
Number of subjects: 50
Study 9306119 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 40
Study 9306119 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-analogue
Number of subjects: 40
Study 9306119 — intervention group
Group type: COMPARATOR
Intervention: No pretreatment
Number of subjects: 40
Study 9306119 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestagen
Number of subjects: 40
Study 8290673 — intervention group
Group type: EXPERIMENTAL
Intervention: Thioridazine
Number of subjects: 35
Study 8290673 — intervention group
Group type: COMPARATOR
Intervention: Molindone
Number of subjects: 35
Study 8290673 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 35
Study 2885188 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium
Number of subjects: 30
Study 2885188 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 30
Study 31188705 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Lifestyle Program (ALP; n = 17)
Number of subjects: 31
Study 31188705 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (n = 14)
Number of subjects: 31
Study 29306465 — intervention group
Group type: EXPERIMENTAL
Intervention: fQRS at 60 minutes post-PCI
Number of subjects: 421
Study 29306465 — intervention group
Group type: COMPARATOR
Intervention: No fQRS at 60 minutes post-PCI
Number of subjects: 421
Study 27212247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment (15‐20mg/kg/day) for 24 weeks
Number of subjects: 34
Study 27212247 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 34
Study 27212247 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) treatment
Number of subjects: 34
Study 24697979 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-administration of naproxen 500 mg and apixaban 10 mg
Number of subjects: 21
Study 24697979 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen 500 mg
Number of subjects: 21
Study 24697979 — intervention group
Group type: COMPARATOR
Intervention: Apixaban 10 mg
Number of subjects: 21
Study 22331037 — intervention group
Group type: EXPERIMENTAL
Intervention: High soy diet (2 soy food servings per day)
Number of subjects: 82
Study 22331037 — intervention group
Group type: COMPARATOR
Intervention: Low soy diet (<3 servings per week)
Number of subjects: 82
Study 20386992 — intervention group
Group type: EXPERIMENTAL
Intervention: Interim methadone (IM)
Number of subjects: 319
Study 20386992 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (Control)
Number of subjects: 319
Study 19045972 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-based behavioral intervention (12 sessions over 3 months)
Number of subjects: 130
Study 19045972 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (no treatment during intervention period)
Number of subjects: 130
Study 15770007 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate cancer screening using PSA testing and DRE
Number of subjects: 38350
Study 15770007 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic follow-up after positive screening tests
Number of subjects: 38350
Study 12858327 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 12
Study 12858327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 10630793 — intervention group
Group type: EXPERIMENTAL
Intervention: AIK-C vaccine
Number of subjects: 135
Study 10630793 — intervention group
Group type: COMPARATOR
Intervention: Schwarz vaccine
Number of subjects: 135
Study 10630793 — intervention group
Group type: COMPARATOR
Intervention: Both vaccines
Number of subjects: 135
Study 7717832 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted dose heparin
Number of subjects: 360
Study 7717832 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent pneumatic compression (IPC)
Number of subjects: 360
Study 7717832 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (FES)
Number of subjects: 360
Study 7717832 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 360
Study 2044396 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac sodium (75 mg)
Number of subjects: 107
Study 2044396 — intervention group
Group type: COMPARATOR
Intervention: Dipyrone/spasmolytics
Number of subjects: 107
Study 2044396 — intervention group
Group type: COMPARATOR
Intervention: Pethidine (75 mg)
Number of subjects: 107
Study 7314025 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline and salbutamol together
Number of subjects: 29
Study 7314025 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol
Number of subjects: 29
Study 7314025 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised salbutamol and aminophylline
Number of subjects: 29
Study 7314025 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol and aminophylline
Number of subjects: 29
Study 7314025 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 29
Study 30831045 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine eye drop (3 drops applied in four directions)
Number of subjects: 70
Study 30831045 — intervention group
Group type: COMPARATOR
Intervention: Placebo or synthetic teardrop (3 drops applied in four directions)
Number of subjects: 70
Study 28698876 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI TLIF)
Number of subjects: 80
Study 28698876 — intervention group
Group type: COMPARATOR
Intervention: Standard Transforaminal Lumbar Interbody Fusion (S TLIF)
Number of subjects: 80
Study 26229203 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia informed consent tool
Number of subjects: 311
Study 26229203 — intervention group
Group type: COMPARATOR
Intervention: Standard procedure
Number of subjects: 311
Study 23123509 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-P/C (nab-paclitaxel 100 mg/m² weekly)
Number of subjects: 1052
Study 23123509 — intervention group
Group type: COMPARATOR
Intervention: sb-P/C (solvent-based paclitaxel 200 mg/m² day 1 every 3 weeks)
Number of subjects: 1052
Study 23123509 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-P/C
Number of subjects: 1052
Study 23123509 — intervention group
Group type: COMPARATOR
Intervention: sb-P/C
Number of subjects: 1052
Study 21330355 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus on Kids (FOK) program
Number of subjects: 304
Study 18367182 — intervention group
Group type: EXPERIMENTAL
Intervention: HP-hFSH
Number of subjects: 152
Study 18367182 — intervention group
Group type: COMPARATOR
Intervention: rFSH
Number of subjects: 152
Study 17768297 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 0
Study 15030824 — intervention group
Group type: EXPERIMENTAL
Intervention: Healon5
Number of subjects: 157
Study 15030824 — intervention group
Group type: COMPARATOR
Intervention: Healon
Number of subjects: 157
Study 11302829 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole oral solution
Number of subjects: 0
Study 9463082 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of serum IgG class anti-CMV antibodies in women following spontaneous abortions (n=11)
Number of subjects: 26
Study 9463082 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of serum IgG class anti-HPV-B19 antibodies in women following spontaneous abortions (n=11)
Number of subjects: 26
Study 9463082 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of IgM and IgG class antibodies against CMV and HPV-B19 in one patient
Number of subjects: 26
Study 9463082 — intervention group
Group type: COMPARATOR
Intervention: Control group of women in the second trimester of a normal pregnancy (n=15)
Number of subjects: 26
Study 8201852 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 16000
Study 8201852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16000
Study 3236319 — intervention group
Group type: EXPERIMENTAL
Intervention: Random zero sphygmomanometer
Number of subjects: 36
Study 3236319 — intervention group
Group type: COMPARATOR
Intervention: Standard sphygmomanometer
Number of subjects: 36
Study 3236319 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm supported position
Number of subjects: 36
Study 3236319 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm dependent position
Number of subjects: 36
Study 2195714 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (30 mg q.i.d. for 28 days)
Number of subjects: 164
Study 2195714 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical tablets for 28 days)
Number of subjects: 164
Study 1096900 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 0
Study 1096900 — intervention group
Group type: COMPARATOR
Intervention: Acetyl salicylic acid (ASA)
Number of subjects: 0
Study 29777529 — intervention group
Group type: EXPERIMENTAL
Intervention: ADS-5102 (210, 274, or 338 mg)
Number of subjects: 0
Study 29777529 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28203003 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (medication group, low dose aspirin)
Number of subjects: 69
Study 28203003 — intervention group
Group type: COMPARATOR
Intervention: Group B (withdrawal group)
Number of subjects: 69
Study 28203003 — intervention group
Group type: COMPARATOR
Intervention: Group C (control group)
Number of subjects: 69
Study 26335129 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard salpingectomy (Group A, n = 91)
Number of subjects: 186
Study 26335129 — intervention group
Group type: COMPARATOR
Intervention: Wide salpingectomy with mesosalpinx removal (Group B, n = 95)
Number of subjects: 186
Study 23400807 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Relevant
Number of subjects: 0
Study 23400807 — intervention group
Group type: COMPARATOR
Intervention: Group Irrelevant
Number of subjects: 0
Study 21077915 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate ICD shocks
Number of subjects: 100
Study 21077915 — intervention group
Group type: COMPARATOR
Intervention: Appropriate ICD shocks
Number of subjects: 100
Study 21077915 — intervention group
Group type: EXPERIMENTAL
Intervention: Inappropriate ICD shocks (multivariable analysis)
Number of subjects: 100
Study 21077915 — intervention group
Group type: EXPERIMENTAL
Intervention: Consideration of device deactivation
Number of subjects: 100
Study 19465316 — intervention group
Group type: EXPERIMENTAL
Intervention: Detained youth
Number of subjects: 1653
Study 19465316 — intervention group
Group type: COMPARATOR
Intervention: Males living in the community
Number of subjects: 1653
Study 19465316 — intervention group
Group type: COMPARATOR
Intervention: Males incarcerated at follow-up
Number of subjects: 1653
Study 16737871 — intervention group
Group type: COMPARATOR
Intervention: 50% RH
Number of subjects: 22
Study 16737871 — intervention group
Group type: EXPERIMENTAL
Intervention: 75% RH
Number of subjects: 22
Study 15090564 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous IFN beta‐1a, 22 micro g once weekly
Number of subjects: 371
Study 15090564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 371
Study 11715631 — intervention group
Group type: EXPERIMENTAL
Intervention: Rob 10 (3 x 25 drops daily)
Number of subjects: 88
Study 11715631 — intervention group
Group type: EXPERIMENTAL
Intervention: Rob 10
Number of subjects: 88
Study 9207816 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 prenatal visits (experimental group)
Number of subjects: 2328
Study 9207816 — intervention group
Group type: COMPARATOR
Intervention: 14 prenatal visits (control group)
Number of subjects: 2328
Study 8087826 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion for 24 hours
Number of subjects: 20
Study 8087826 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine administration after nitroglycerin infusion
Number of subjects: 20
Study 2969906 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 20
Study 2969906 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment (CIT)
Number of subjects: 20
Study 31863269 — intervention group
Group type: COMPARATOR
Intervention: Cancer-facts writing condition (CTL group)
Number of subjects: 118